Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Research & Development is the aggregate amount of research and development expenses during the year. PT Soho Global Health Tbk's Research & Development for the
three
months ended in Jun. 2026 was Rp9,017 Mil.
Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was Rp32,566 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Soho Global Health Tbk Research & Development Chart
PT Soho Global Health Tbk Research & Development Calculation
This is the expense the company spent on research and development.
Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp32,566 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Research & Development of Rp32,566 Mil mean?
PT Soho Global Health Tbk (ISX:SOHO) has a Research & Development of Rp32,566 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on PT Soho Global Health Tbk and its competitors.
Is PT Soho Global Health Tbk's Research & Development too high?
PT Soho Global Health Tbk's current Research & Development is Rp32,566 Mil. Overall, PT Soho Global Health Tbk has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Soho Global Health Tbk's Research & Development compare to MCK and COR?
PT Soho Global Health Tbk's Research & Development of Rp32,566 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PT Soho Global Health Tbk and its competitors. PT Soho Global Health Tbk's current Research & Development is Rp32,566 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Soho Global Health Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Soho Global Health Tbk (ISX:SOHO) is currently considered Significantly Overvalued. The stock's GF Value™ is Rp805.04, compared to a current price of Rp1,205.00 — trading 49.7% above its estimated fair value. The current Research & Development is Rp32,566 Mil. PT Soho Global Health Tbk's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PT Soho Global Health Tbk (ISX:SOHO), the current Research & Development is Rp32,566 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Soho Global Health Tbk (ISX:SOHO) Overvalued in 2026?
Based on GuruFocus' analysis, PT Soho Global Health Tbk stock appears to be overvalued.
The current stock price of Rp1,205.00 is trading 49.7% above its estimated GF Value™ of Rp805.04.
GuruFocus considers PT Soho Global Health Tbk to be Significantly Overvalued.
Key valuation signals for ISX:SOHO:
Research & Development: Rp32,566 Mil
GF Value™: Rp805.04 vs. price of Rp1,205.00 (49.7% above fair value)
No single metric tells the full story. See the ISX:SOHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Soho Global Health Tbk is a healthcare company operating in the areas of natural/herbal health care products and services. The company manufactures and distributes pharmaceutical products, including herbal cures, proprietary medicines, and health foods, under various brand names such as Curcuma Plus, Curcuma Plus Milk; Imboost; Fitkom; Diapet; Laxing; Lelap; Asthma Soho, and Sohobion. Its segment includes Distribution, Consumer health, Alliance, and others. The company generates maximum revenue from the Distribution segment.
85GF Score
Get the complete analysis for ISX:SOHO
Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SOHO has been successfully added to your 
